Naproxcinod 750 mg non-inferior to naproxen in the reduction of knee OA symptoms
Efficacy and safety of naproxcinod in the treatment of patients with osteoarthritis of the knee: A 13-week prospective, randomized, multicenter studyOsteoarthritis Cartilage. 2010 May;18(5):629-39. Epub 2010 Feb 16
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
918 patients (>=40 yr) with osteoarthritis (OA) of the knee and managed with oral NSAIDs or acetaminophen, were randomized to 4 groups of either naproxcinod (750 or 375 mg), naproxen (50 mg) or a placebo. At study conclusion (i.e. 13 weeks), naproxcinod was found to be well-tolerated and did not significantly elevate blood pressure more than naproxen. Naproxcinod's clinical efficacy is statistical...
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.Continue